Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

t or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; (iv) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates; and (v) the timing and success of the company's efforts to establish and maintain future collaboration partnerships on attractive commercial terms or at all. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit www.nektar.com.

    Contact:
    Jennifer Ruddock, 650-631-4954
    Nektar Therapeutics

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, August 6, 2015 to ... developments. Interested parties may access the live ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... a special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates ... continue highlighting the success of the prescription drug benefit, commonly referred to as Part ... infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... 20, 2011 Reportlinker.com announces that a ... its catalogue: Orthopaedics: Market ... http://www.reportlinker.com/p0573671/Orthopaedics-Market-Prospects-GlobalCompetition .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine ... is projected to be 5% over the ...
... 19, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... its subsidiary, Valeant International (Barbados) SRL ("VIB"), has entered ... the Canadian marketing and distribution rights to Zuacta™, a ... used in conjunction with oral COX-2 inhibitors or NSAIDs ...
Cached Medicine Technology:Orthopaedics: Market Prospects & Global Competition 2Orthopaedics: Market Prospects & Global Competition 3Orthopaedics: Market Prospects & Global Competition 4Orthopaedics: Market Prospects & Global Competition 5Orthopaedics: Market Prospects & Global Competition 6Orthopaedics: Market Prospects & Global Competition 7Orthopaedics: Market Prospects & Global Competition 8Orthopaedics: Market Prospects & Global Competition 9Orthopaedics: Market Prospects & Global Competition 10Orthopaedics: Market Prospects & Global Competition 11Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada 2
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have ... the Apple AppStore. , The app is designed to track various metrics of ... tool to view personal health and use this information for positive behavior modification. Lume ...
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... ... ... Ticket Down is a reliable source for authentic tickets for the 2015 ... festival will end on Sunday, August 2nd. , Music fans have traveled ... unique and unbelievably popular festival attracts the best in entertainment from around the world. ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... its new store run by GoodThreads. The store can be accessed by visiting ... designs, many of which are customizable. The best part: whenever a product is ...
Breaking Medicine News(10 mins):Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... Toxins can be removed and pollutants can be trapped through ... study. The local water quality can also be improved as ... has been around for 10 to 15 years, but there ... US researchers at the University of Connecticut planted two rain ...
... Hong Kong’s Life of Life Healing Spa is increasingly getting ... fat after the very first session. // Owner Karen Chu ... a good degree of success since the spa first began ... fire treatment given here has not yet resulted in any ...
... chances of quitting smoking as the presence of nicotine from ... from inhaled source leading to loss of interest in smoking ... researchers have reported their finding in the Journal Nicotine and ... occurring due to use of nicotine patches. ,Professor ...
... William Honer and researchers have reported the results of ... which they found in a trial conducted in 68 ... drugs Clozapine and Risperdal for treatment of Schizophrenia. ... not work positively in controlling the symptoms of Schizophrenia ...
... system has been claimed by British Columbia, in spite of ... services // are concerned. The worst health system in the ... last in terms of patient satisfaction and performance. The Conference ... ,Money does not appear to play a prominent where good ...
... that he has a plan that will enable the uninsured ... // The taxpayers, employers and the recipients of the insurance ... the potential to benefit tens of thousands of city residents. ... care legislation said that he supports the mayor's idea and ...
Cached Medicine News:Health News:San Francisco Mayor Proposes An Alternate Plan For The Uninsured City Residents 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: